The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician.
The objectives of the registry include to evaluate the safety and long-term effectiveness of velaglucerase alfa, to characterize patients receiving velaglucerase alfa or other Gaucher Disease-specific treatments, to gain a better understanding of the natural history of GD and to serve as a database for evidence-based management of Gaucher Disease over time in real-life clinical practice.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients of any age or gender with confirmed diagnosis (biochemical and/or genetic) of Gaucher disease
* Signed and dated written informed consent from the patient or, for patients aged \<18 years (\<16 years in the United Kingdom \[UK\]), their parent and/or legally authorized representatives (LAR), and assent of the minor where applicable. Legally authorized representatives are also applicable for cognitively impaired patients.
Exclusion Criteria:
\- Patients currently enrolled in ongoing blinded clinical trials (drugs or devices; includes all blinded trials)
Primary outcome measure(s)
Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — Baseline to one year for up to 20 years Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) that either commenced or worsened following the first dose of VPRIV.
Number of Participants With Infusion-related Reactions (IRRs) — Baseline to one year for up to 20 years An IRR is defined as an AE that has been assessed as at least possibly related to treatment with VPRIV and occurs during an infusion or up to 24 hours post-VPRIV infusion.
Increase of Hemoglobin Concentration — Baseline to one year for up to 20 years Hemoglobin concentration will be assessed.
Increase of Platelet Count — Baseline to one year for up to 20 years Platelet count will be assessed.
Decrease in Liver Volume — Baseline to one year for up to 20 years Liver volume will be assessed by abdominal imaging.
Decrease in Spleen Volume — Baseline to one year for up to 20 years Spleen volume will be assessed by abdominal imaging.
Increase in Bone Mineral Density (BMD) — Baseline to one year for up to 20 years Bone mineral density will be assessed.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.